ABOS
Acumen Pharmaceuticals Inc
NASDAQ: ABOS · HEALTHCARE · BIOTECHNOLOGY
$2.34
-4.88% today
Updated 2026-04-29
Market cap
$169.01M
P/E ratio
—
P/S ratio
538.78x
EPS (TTM)
$-2.00
Dividend yield
—
52W range
$1 – $4
Volume
0.6M
Acumen Pharmaceuticals Inc (ABOS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.70M | $1.44M | $1.44M | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -15.4% | +0.0% | -100.0% | — | — | — |
| Cost of revenue | $8.58M | $8.00M | $12.30M | $169000.00 | $42.32M | $178000.00 | $184000.00 |
| Gross profit | $-6.88M | $-6.56M | $-12.30M | $-169000.00 | $-42.32M | $-178000.00 | $-184000.00 |
| Gross margin | -405.4% | -456.9% | -856.9% | — | — | — | — |
| R&D | $8.58M | $8.00M | $12.30M | $32.36M | $42.32M | $93.80M | $104.89M |
| SG&A | $926000.00 | $1.35M | $7.28M | $12.88M | $18.82M | $20.22M | $18.95M |
| Operating income | $-7.80M | $-7.91M | $-19.58M | $-45.24M | $-61.14M | $-114.02M | $-123.83M |
| Operating margin | -459.9% | -551.0% | -1363.8% | — | — | — | — |
| EBITDA | $119000.00 | $-7.91M | $-19.58M | $-42.69M | $-51.61M | $-98.08M | $-123.83M |
| EBITDA margin | 7.0% | -551.0% | -1363.5% | — | — | — | — |
| EBIT | $-7.69M | $-7.33M | $-19.58M | $-42.86M | $-51.79M | $-98.26M | — |
| Interest expense | $0.00 | $0.00 | $81.02M | $2.38M | $581000.00 | $4.07M | $4.22M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-7.91M | $-7.33M | $-100.61M | $-42.86M | $-52.37M | $-102.33M | $-121.33M |
| Net income growth (YoY) | — | +7.4% | -1273.5% | +57.4% | -22.2% | -95.4% | -18.6% |
| Profit margin | -465.9% | -510.1% | -7006.0% | — | — | — | — |